Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy).
Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...